Travis Lee Stiles
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$5.5MFederal grants as PI13 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
13 awards · $5.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 3, 2026 | NIH | SBIR Phase II Human iPSC neural spheroids to screen for compounds that block tau propagation | $1.2M | NOVORON BIOSCIENCE INC |
| Sep 16, 2025 | NIH | SBIR Phase II Human iPSC neural spheroids to screen for compounds that block tau propagation | $1.3M | NOVORON BIOSCIENCE INC |
| Aug 11, 2022 | NIH | STTR Phase I A novel approach to restricting the spread of neurofibrillary tau | $110K | NOVORON BIOSCIENCE INC |
| Aug 10, 2022 | NIH | STTR Phase I A novel approach to restricting the spread of neurofibrillary tau | $348K | NOVORON BIOSCIENCE INC |
| Apr 29, 2022 | NIH | STTR Phase I A novel approach to restricting the spread of neurofibrillary tau | $37K | NOVORON BIOSCIENCE INC |
| Aug 31, 2021 | NIH | STTR Phase I A novel approach to restricting the spread of neurofibrillary tau | $350K | NOVORON BIOSCIENCE INC |
| Jun 10, 2020 | NIH | STTR Phase I NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS | $354K | NOVORON BIOSCIENCE INC |
| Sep 6, 2019 | NIH | STTR Phase I NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS | $353K | NOVORON BIOSCIENCE INC |
| Mar 15, 2019 | NIH | SBIR Phase I Assessment of NOVO-118 as a regenerative therapeutic in acute spinal cord injury | $348K | NOVORON BIOSCIENCE INC |
| Mar 19, 2018 | NIH | SBIR Phase I Assessment of NOVO-118 as a regenerative therapeutic in acute spinal cord injury | $348K | NOVORON BIOSCIENCE INC |
| Sep 9, 2016 | NIH | SBIR Phase I RAP as a novel therapeutic to promote remyelination after MS demyelinating event | $321K | NOVORON BIOSCIENCE INC |
| Sep 14, 2015 | NIH | SBIR Phase I RAP as a novel therapeutic to promote remyelination after MS demyelinating event | $353K | NOVORON BIOSCIENCE INC |
| Apr 6, 2015 | NIH | STTR Phase I RAP as a therapeutic compound for neuronal regeneration after spinal cord injury | $80K | NOVORON BIOSCIENCE INC |
Peer ranks
Federal funding#229
Awards as PI#72
Patents#273
Companies
- NOVORON BIOSCIENCE INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.